VolitionRx Limited Announces 1-for-20 Reverse Stock Split Effective April 28, 2026

HENDERSON, NV, April 17, 2026 — VolitionRx Limited (NYSE American: VNRX), a life sciences company specializing in in vitro and in vivo diagnostic substances, has announced a significant corporate action that is likely to impact its stock and shareholders. The company is set to implement a 1-for-20 reverse stock split of its outstanding common shares, effective at 12:01 a.m. Eastern Time on April 28, 2026. Trading on a split-adjusted basis will commence at market open on the same day.

Key Highlights of the Announcement

• Reverse Stock Split Ratio: 1-for-20. Every 20 shares of issued and outstanding common stock will be automatically consolidated into one share.
• Effective Date: April 28, 2026, at 12:01 a.m. ET. Split-adjusted trading starts at market open on April 28, 2026.
• No Fractional Shares: Shareholders entitled to fractional shares will receive one whole share in lieu of a fraction. Outstanding warrants, options, equity awards, and other equity instruments will be rounded up to the next whole share, or cash will be paid for fractions as per instrument terms.
• Proportionate Adjustments: All outstanding equity incentive awards (including under the 2015 and 2024 Stock Incentive Plans), warrants, convertible notes, and shares available for future issuance will be adjusted according to the 1-for-20 ratio.
• Shareholder Approval: The reverse split was approved at a special meeting held on March 31, 2026, empowering the company’s Board of Directors to determine the specific ratio within a previously approved range.
• Reason for Split: The split is a key condition stemming from financing agreements with Lind Global Asset Management XII LLC, closed on May 20, 2025, and January 15, 2026.

Why This Matters to Investors

• Potential Price Sensitivity: Reverse stock splits are material corporate events and can significantly affect share prices, market capitalization, and trading liquidity. Typically, such splits are used to regain compliance with exchange listing requirements or improve the perceived value per share.
• Exchange Listing: VolitionRx’s common stock will continue trading under the ticker symbol “VNRX” on the NYSE American.
• No Action Required: The split and adjustment process will be automatic for shareholders. No new stock certificates are necessary unless requested by the holder.
• Instruments Affected: The conversion affects not only common shares but also all outstanding options, warrants, convertible notes, and reserved shares for future issuance, with all being adjusted in line with the 1-for-20 split.

Details for Shareholders

Shareholders are reminded that:

• No fractional shares will be issued. Any shareholder who would otherwise receive a fractional share will be rounded up to receive a whole share, or, if specified by the terms of the relevant security (such as a warrant or option), may receive cash for the fractional amount.
• All related equity incentive awards, warrants, notes, and other equity-linked instruments will be subject to proportionate adjustment, ensuring holders maintain the same overall percentage ownership and rights post-split, albeit at a lower share count and higher share price if market capitalization remains constant.

Corporate Information

• Company Name: VolitionRx Limited
• Business Address: 1489 West Warm Springs Road, Suite 110, Henderson, NV 89014
• Contact: +1 (512) 774-8930
• Exchange: NYSE American
• Ticker Symbol: VNRX
• Entity Tax ID: 91-1949078

Leadership Signature

The filing was signed by Cameron Reynolds, Chief Executive Officer & President, on April 17, 2026.

Potential Impact on Share Price

Reverse stock splits often have a significant impact on the market. They are sometimes interpreted as efforts to maintain exchange listing standards (e.g., minimum price requirements) or as responses to dilution from prior financings. While the reverse split does not change the company’s total market value or shareholders’ proportional ownership, it reduces the number of shares outstanding, which could affect liquidity and investor perception.

Investors should monitor the company’s communications and market developments closely leading up to and following the effective date. The split is particularly notable because it directly ties to recent financing agreements, which may signal ongoing capital needs or strategic shifts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with their financial advisor before making any investment decisions. The author and publisher are not responsible for any actions taken based on the information provided herein.

View VOLITIONRX LTD Historical chart here